Search results
Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 7 hours agoPrevnar sales inched 2% ahead to $6.44 billion. But other key products saw downfalls. Revenue from...
Wedbush Lowers Biogen (NASDAQ:BIIB) Price Target to $213.00
ETF DAILY NEWS· 6 days agoBiogen (NASDAQ:BIIB – Get Free Report) had its price target decreased by equities research analysts at Wedbush from $245.00 to $213.00 in a research report issued to clients and investors on ...
UBS Group Trims Amgen (NASDAQ:AMGN) Target Price to $284.00
ETF DAILY NEWS· 5 days agoAmgen (NASDAQ:AMGN – Free Report) had its price objective trimmed by UBS Group from $314.00 to $284.00 in a research note released on Wednesday morning, Benzinga reports. The brokerage currently ...
Greenleaf Trust Increases Position in Biogen Inc. (NASDAQ:BIIB)
ETF DAILY NEWS· 2 days agoGreenleaf Trust increased its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 20.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission ...
Biogen Inc. (NASDAQ:BIIB) to Post Q3 2024 Earnings of $4.13 Per Share, Wedbush Forecasts
ETF DAILY NEWS· 5 days agoBiogen Inc. (NASDAQ:BIIB – Free Report) – Investment analysts at Wedbush raised their Q3 2024 earnings estimates for Biogen in a research note issued to investors on Wednesday, April 17th. Wedbush ...
Desjardins Global Asset Management Inc. Has $115,000 Holdings in Biogen Inc. (NASDAQ:BIIB)
ETF DAILY NEWS· 5 days agoDesjardins Global Asset Management Inc. cut its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 86.0% in the 4th quarter, according to its most recent Form 13F filing with the ...
Biogen (NASDAQ:BIIB) Price Target Cut to $214.00
ETF DAILY NEWS· 6 days agoBiogen (NASDAQ:BIIB – Get Free Report) had its price target reduced by equities research analysts at UBS Group from $250.00 to $214.00 in a research note issued on Wednesday, Benzinga reports ...